Johnson & Johnson

Johnson & Johnson

Yahoo Finance • 1 hour ago

Pfizer (PFE) Stock Looks Attractive for Income Investors

Pfizer (PFE) stock looks attractive for income investors because of its well-covered dividend and modest valuation. The drug maker's shares have outperformed the S&P 500 (SPX) in 2026, mirroring the strong performance of the healthcare sec... Full story

Yahoo Finance • 1 hour ago

Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MIMRYLO™ (rusfertide) Approved by FDA for the Treatment of Erythrocytosis in Adults with Polycythemia Vera; Approval Triggered $275 Million in Payments to Protagonist Comprehensive Phase 2b Program with PN-881, an Oral IL-17 Antagonist fo... Full story

Yahoo Finance • 4 hours ago

Genmab nine-month revenue rises 22% as late-stage pipeline delivers

Investing.com -- Genmab reported a 22% rise in revenue for the first nine months of 2026 on Thursday, driven by higher royalties from Darzalex and Kesimpta and stronger sales of its cancer drug Epkinly. The Danish biotech maintained its fu... Full story

Yahoo Finance • 11 hours ago

What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Nov. 3

This article first appeared on GuruFocus. State Street Health Care Select Sector SPDR ETF (XLV) recorded $330.3 million in net buying on Tuesday, Nov. 3, with gross ETF activity matching that figure and no positions reduced. All 60 holdin... Full story

Yahoo Finance • yesterday

CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index

BOSTON, Nov. 4, 2026 /PRNewswire/ -- Sanofi ranked first in the 2026 CNS Summit Digital Innovation Index, developed in collaboration with IDEA Pharma, a division of SAI MedPartners, placing in the top three in all three categories. The ran... Full story

Yahoo Finance • yesterday

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Curis Inc. 116,764,683 1.60 1.08 1.195 +0.4811 Helport AI Ltd 105,961,21... Full story

Yahoo Finance • yesterday

State Street Health Care SPDR (XLV) Adds Eli Lilly and J&J on Nov. 2

This article first appeared on GuruFocus. State Street Health Care Select Sector SPDR ETF (XLV) was buying on Monday, with 60 positions increased and none decreased, and no ETFs selling. The fund's ETF activity totaled $175.3 million boug... Full story

Yahoo Finance • 2 days ago

Most and least shorted mid- to mega-cap healthcare stocks at the end of October

Short interest data from late October 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in high-volatility biotechnology, equipment, and digital health names, wi... Full story

Yahoo Finance • 3 days ago

Johnson & Johnson (JNJ) As Impella Data Fuels The Story, Is The Stock Fully Valued?

Johnson & Johnson (JNJ) is back in focus after new clinical analyses at the TCT 2026 symposium linked its Impella heart pumps to lower in-hospital and short term mortality in high risk coronary procedures. After the latest Impella data hi... Full story

Yahoo Finance • 3 days ago

What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Oct. 29

This article first appeared on GuruFocus. State Street Health Care Select Sector SPDR ETF (XLV) reported $423.4 million in ETF activity last Thursday, all of it buying. The $49.10 billion fund increased all 60 of its positions and decreas... Full story

Yahoo Finance • 3 days ago

ETFs Bought $22.0 Million of Merck (MRK) on Oct. 29

This article first appeared on GuruFocus. ETFs bought $22.0 million of Merck (MRK) on Thursday, with 36 funds adding shares against 20 that sold. ETF activity has favored the stock for four straight sessions, including $19.1 million on We... Full story

Yahoo Finance • 3 days ago

UnitedHealth (UNH) Sees $35.0 Million in Net ETF Buying on Oct. 29

This article first appeared on GuruFocus. ETF flows into UnitedHealth stretched to a fourth straight day on Thursday, with $35.0 million in net buying. That followed net purchases of $17.8 million on Wednesday, $16.4 million on Tuesday an... Full story

Yahoo Finance • 3 days ago

ETFs Are Buying Johnson & Johnson (JNJ) on Oct. 29

This article first appeared on GuruFocus. Forty-two ETFs were buying Johnson & Johnson (JNJ) versus 21 selling in Thursday's session, for net buying of $35.1 million by dollar value. The move extended a four-day buying streak. Net inflows... Full story

Yahoo Finance • 4 days ago

What Is Johnson & Johnson (JNJ) Signaling With Its New Impella Heart Pump Data?

Johnson & Johnson (NYSE:JNJ) reported positive real-world outcomes for its Impella heart pumps at the TCT 2026 meeting on 2 November 2026. Registry data from U.S. and European hospitals showed Impella use in high-risk percutaneous coronary... Full story

Yahoo Finance • 4 days ago

5 Most Undervalued Dividend Growth Stocks According to Hedge Funds

Dividend-paying stocks can be an important part of a long-term investment portfolio because they let investors earn steady income while also participating in the stock market's growth. Companies with established dividend policies are gener... Full story

Yahoo Finance • 4 days ago

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

Analyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may help improve outcomes during and after complex heart procedures SAN DIEGO, November 01, 2026--(BUSINESS WIRE)--Johnson & J... Full story

Yahoo Finance • 6 days ago

3 Biotech Stocks With Upside Of Up To 80%

Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, high potential biotech... Full story

Yahoo Finance • 6 days ago

How Investors Are Reacting To Johnson & Johnson Stock New Drug Progress

Johnson & Johnson has released a string of positive trial readouts and product updates in oncology, immunology and MedTech, including data for subcutaneous amivantamab, JNJ-6143 and TREMFYA, alongside new device launches and regulatory mil... Full story

Yahoo Finance • 7 days ago

Does Johnson & Johnson (JNJ) Have A New Edge In Plaque Psoriasis?

Johnson & Johnson (NYSE: JNJ) is seeing quick uptake of its oral plaque psoriasis therapy Icotyde in U.S. dermatology practices. New independent physician research reports Icotyde prescriptions are building momentum and gaining share withi... Full story

Yahoo Finance • 7 days ago

Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference

SAN DIEGO, October 29, 2026--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrot... Full story